Medpage Today on MSN9d
Have the New Pulmonary Hypertension Drugs Changed the Game?In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this ...
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...
In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.
Cibotercept is under clinical development by Keros Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension.
A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...
The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...
Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair ...
Pulmonary arterial hypertension (PAH) affected an estimated 192,000 individuals globally in 2021, disproportionately affecting women and older adults.
Steve Van Wormer has published nearly 500 podcasts about pulmonary hypertension (PH) — more than perhaps anyone working in rare diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback